Navigation Links
Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

– Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2012, that full year 2013 EBITDA will be between $62 and $68 million, that capital expenditures will be approximately $36 to $40 million and that depreciation will be $22 to $24 million in 2013.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2011, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2011, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, governmental legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products, as well as risks relating to a Phase 3 supply agreeme
'/>"/>
SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cambrex Reports First Quarter 2012 Results
2. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
3. Cambrex Announces Significant New Supply Agreement
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Reports Third Quarter 2012 Financial Results
6. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
11. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... , ZURICH, Aug. 27 /PRNewswire/ -- Nycomed ... four phase III trials have been published in the prestigious peer-reviewed medical ... a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in ... COPD is an under-diagnosed progressive lung disease that may lead to ...
... , , ... WaveSense blood glucose meters, announced today their continued commitment to ... blood glucose meter (BGM) accuracy for all patients. WaveSense BGM,s ... world class accuracy. They detect and correct for errors caused ...
Cached Medicine Technology:Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks 2WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks 3
(Date:8/22/2014)... Dealing with a drug or alcohol addiction is never ... child. Adolescent substance abuse has been an important issue among ... new helpline is now providing a valuable resource for teens ... like a teen drug addiction . , The ... positive impact in the community. By calling (513) 318-1603, parents ...
(Date:8/22/2014)... Aid in Recovery, a full service drug ... a recent bill introduced in the Philippines ... legislator and retired police general. In House Bill 4451, ... rather than imprisonment. Aid in Recovery points to this ... the drug addiction epidemic. , The bill, introduced this ...
(Date:8/21/2014)... Os-Monitor.com, an outstanding online supplier of useful software ... collection ( http://www.os-monitor.com ). In addition to that, ... high end items are offered with greatly discounted ... productivity, the employers pay more attention to their ... network monitoring software products are becoming more and ...
(Date:8/21/2014)... Recently, Top10BestSEOHosting.com has compared many professional SEO hosting companies ... the most reliable suppliers for webmasters who want to ... boom in websites in recent years, and the new ... of web hosting companies that offer a variety of ... been providing hosting solutions to thousands of business and ...
(Date:8/21/2014)... 2014 Recently, Skmen.com, a distinguished garment supplier, ... girls’ casual dresses . From today until August ... 30 percent off) when they are shopping at the company’s ... outfits are according to the newest quality standards; they are ... charming casual dresses, worldwide ladies can also access the other ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 2Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 3Health News:New Employee Monitoring Software Collection Unveiled By Os-Monitor.com 2Health News:Best SEO Hosting Suppliers in the Global Market Recommended by Top10BestSEOHosting.com 2Health News:Charming Girls’ Casual Dresses Now Released by Distinguished Garment Company Skmen.com 2
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... drugs, used by patients with enlarged hearts// (dilated ... Scientists with the Multicenter defibrillators in Nonischemic ... sudden cardiac deaths with cardiomyopathy due to a ... these about, 229 patients were randomly selected to ...
... A study conducted by Cancer Research UK says 'Teens who tried ... never tried it to take up smoking' //.Again after 3 years ... Research UK said anti-smoking campaigns should focus on preventing children trying ... found around 14% of 11-year olds and 62% of 15-year olds ...
... Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd today said ... US-based Solutia Inc for 74.5 million dollars. // ... for purchasing 100 per cent stake in CarboGen ... in a statement., ,The acquisition includes other ...
... Ranbaxy Laboratories Limited today said the World Health Organistion ... (ARV) products in its pre-qualification list. // ... Efavirenz 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, ... a significant development. We strongly feel that Generic ARVs ...
Cached Medicine News:
... .90 mm (20 g) cannula ... mm in length. Cannula beveled ... 3201 has 16 cm (6 ... to allow injection of heavy ...
PLX90S Sealed CO2 Laser System -- laser head + power supply....
... Ultra MD Super Pulse sealed CO2 surgical ... backed by the experience and support services ... of surgical laser experience. All settings are ... The Ultra MD Super Pulse surgical lasers ...
... Pulse sealed CO2 surgical lasers offer unmatched ... experience and support services of a company ... experience. All settings are available at the ... Super Pulse surgical lasers are compatible with ...
Medicine Products: